Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Functional Imaging to Predict Response to Abemaciclib in Advanced HR+/HER2- Breast Cancer
NCT06179303Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib and fluorofuranylnorprogesterone in breast cancer, sponsored by University of Washington. Primary endpoint: Response to abemaciclib + endocrine therapy up to 2 years. Started Jul 2024; status: recruiting.
02
Drugs
abemaciclibfluorofuranylnorprogesterone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06179303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179303.